Oct 14, 2026 08:06AM
Oct 14, 2026 08:05AM
Sep 30, 2026 08:05AM
Aug 12, 2026 04:05PM
May 18, 2026 10:27AM
May 12, 2026 04:05PM
May 7, 2026 08:05AM Atara Biotherapeutics receives FDA guidance on tabelecleucel resubmission
May 7, 2026 08:05AM
Mar 16, 2026 04:05PM
Mar 12, 2026 08:05AM
Mar 12, 2026 08:05AM
Mar 3, 2026 08:06AM
Mar 3, 2026 08:05AM
Feb 23, 2026 08:00AM Atara Biotherapeutics extends $9 million payment deadline to 2028
Feb 23, 2026 08:00AM
Jan 12, 2026 08:05AM
Jan 12, 2026 08:04AM
Jan 12, 2026 08:00AM
Jan 2, 2026 04:06PM
Nov 21, 2025 06:34AM
Nov 12, 2025 09:00AM Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Nov 3, 2025 09:04AM
Nov 3, 2025 09:00AM
Sep 3, 2025 06:00PM
Sep 3, 2025 06:00PM
Aug 18, 2025 06:25AM
Aug 11, 2025 04:01PM
Jul 24, 2025 08:57AM Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transp
Jul 24, 2025 08:00AM
Jul 24, 2025 08:00AM
Jul 15, 2025 08:00AM
Jul 14, 2025 08:01AM
Jul 14, 2025 08:00AM
May 28, 2025 08:00AM
May 15, 2025 08:35AM Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
May 5, 2025 05:06PM
Mar 7, 2025 04:01PM
Jan 28, 2025 06:41AM
Jan 21, 2025 03:45PM
Jan 21, 2025 07:32AM
Jan 21, 2025 07:30AM
Jan 17, 2025 06:31AM Atara Biotherapeutics (ATRA) PT Lowered to $17 at Canaccord Genuity
Jan 16, 2025 08:56AM
Jan 16, 2025 08:35AM
Jan 16, 2025 08:30AM
Nov 12, 2024 04:01PM
Aug 12, 2024 05:00PM
Jul 17, 2024 09:01AM
Jul 17, 2024 09:00AM Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transpl
Jun 21, 2024 04:01PM

336,292 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All